Philips to Introduce AI-Powered, Helium-Free MRI System at RSNA
Offering a variety of AI-enabled tools to facilitate radiology workflow efficiency, the BlueSeal MRI system is reportedly the first wide bore, helium-free 1.5T MRI platform in the field.
Combining artificial intelligence (AI) enhancements for workflow efficiency with a lightweight design and helium-free operation, Philips will unveil the next-generation BlueSeal MRI system at the upcoming 2024 Radiological Society of North America (RSNA) annual meeting in Chicago.
Emphasizing an eco-friendly design, the BlueSeal 1.5T 70 cm MRI system is up to 1,700 kg lighter than comparable systems and the system’s lack of a need for a vent pipe provides additional flexibility with installation, according to Philips.
The next-generation, helium-free BlueSeal 1.5T MRI system will be introduced by Philips at the upcoming 2024 Radiological Society of North America (RSNA) annual meeting in Chicago. (Image courtesy of Philips.)
Philips emphasized that the BlueSeal MRI system also offers a variety of AI-enabled features including:
• automated planning, scanning and image processing for up to 80 percent of MRI procedures with the SmartExam feature;
• a SmartSpeed feature that enables up to 65 percent higher image resolution without additional scan time; and
• integrated imaging and reading with the cloud-based SmartReading technology, which also facilitates enhanced precision diagnosis of neurological conditions and prostate cancer through partnerships with icometrix and Quibim.
“With AI applications seamlessly integrated into our latest 1.5T BlueSeal scanner, we have now applied AI to every aspect of the MRI workflow – from patient setup and high-resolution image capture to quantitative data extraction, advanced diagnostics, and reporting. With this latest innovation, we continue our commitment to deliver wider access to quality MRI to more patients across multiple settings,” noted Ioannis Panagiotelis, Ph.D., the global business leader of MRI at Philips.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
